RBPJ Inhibitor-1
Based on 9 publication(s) in Google Scholar
RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 2682114-39-0
- Formula: C17H14FN3O2
- Molecular Weight:311.31
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Neuronal Signaling Compound Library
HY-L013
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
Publications Citing Use of MedChemExpress (MCE) RBPJ Inhibitor-1
More- Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X. [Abstract]
- Neuro Oncol. 2025 Mar 25:noaf085. [Abstract]
- Cell Death Dis. 2022 Apr 2;13(4):295. [Abstract]
- Arch Pharm Res. 2025 Dec;48(11-12):1382-1398. [Abstract]
- J Immunol. 2026 Jun 7;215(6):vkag074. [Abstract]
- Genomics. 2024 May;116(3):110838. [Abstract]
- Tissue Cell. 2026 Jun:100:103365. [Abstract]
- Int J Lab Hematol. 2025 Jun 12. [Abstract]
- bioRxiv. 2025 Nov 26:2025.11.23.690056. [Abstract]
Customer Validation & Images
-
IF
-
IF
-
WB
-
RT-PCR
-
WB
Biological Activity
RIN1 inhibits the proliferation of hematologic cancer cell lines and promoted skeletal muscle diferentiation from C2C12 myoblasts[1].
RIN1 (0.6 μM, corresponding to 3 × IC50) decreases the number of MHC+ cells and increased the number of nuclei per cell, indicating that it induces the formation of multinucleated myofbers[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AD-293 cells were transfected with RBPJ-VP16myc.
-
Concentration:2 μM.
-
Incubation Time:17 hours.
-
Result:Inhibited Hes1-Luciferase activity with an IC50 of 0.18 µM and Emax of 82%.
Inhibited NOTCH3 ICD with similar potency and efcacy (0.19 µM and Emax=88%).
-
Cell Line:T-cell acute lymphoblastic leukemia (T-ALL) patients (Jurkat and KOPT-K1) and in the mantle cell lymphoma (MCL) line REC-1.
-
Concentration:0.1-10 μM.
-
Incubation Time:96 h.
-
Result:Inhibited NOTCH-dependent tumor cell proliferation.
Was active in both the cancer cell anti-proliferation and myoblast diferentiation assays.
Chemical Information
-
CAS No. 2682114-39-0
-
Appearance Solid
-
Molecular Weight 311.31
-
Formula C17H14FN3O2
-
Color Off-white to light brown
-
SMILES
O=C(N)C1=CC=C(C2=CC=NN2C)C=C1OC3=CC=CC=C3F
-
Synonyms
RIN1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. [Abstract]2024 Jun 18:S1550-4131(24)00189-X. PMID: 38897198
RBPJ Inhibitor-1 purchased from MedChemExpress. Usage Cited in: Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X. [Abstract]
After RBPJ Inhibitor-1 (RIN1) (10 mM; 24 h) treatment in human fibroblast cell line HSF, the expression of NNMT and NOTCH signaling target genes (HES1 and HEY1) was detected by western blotting.
RBPJ Inhibitor-1 purchased from MedChemExpress. Usage Cited in: Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X. [Abstract]
The expression of NNMT and NOTCH signaling target genes (Hes1, Hey1) in m-CAFs treated with RBPJ Inhibitor-1 (RIN1) (10 mM; 24 h) was detected by qRT-PCR.
-
Neuro Oncol
SOX2 commands LIM homeobox transcription factors in choroid plexus development and tumorigenesis. [Abstract]2025 Mar 25:noaf085. PMID: 40128799
RBPJ Inhibitor-1 purchased from MedChemExpress. Usage Cited in: Neuro Oncol. 2025 Mar 25:noaf085. [Abstract]
RBPJ Inhibitor-1 (RIN1) (10 µM) significantly decreased SOX2 expression in NOTCH-driven CP tumor cells.
RBPJ Inhibitor-1 purchased from MedChemExpress. Usage Cited in: Neuro Oncol. 2025 Mar 25:noaf085. [Abstract]
RBPJ Inhibitor-1 (RIN1) (10 µM) significantly decreased LMX1B expression in NOTCH-driven CPP cells.
-
Cell Death Dis
The RBPJ/DAPK3/UBE3A signaling axis induces PBRM1 degradation to modulate the sensitivity of renal cell carcinoma to CDK4/6 inhibitors. [Abstract]2022 Apr 2;13(4):295. PMID: 35368029
RBPJ Inhibitor-1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Apr 2;13(4):295. [Abstract]
RBPJ Inhibitor-1 (RIN1) (1-10 μM) decreased DAPK3 gradually in 786-O cells.
-
Arch Pharm Res
Inhibition of RBPJ transcription complex promotes IL-17 and IFN-γ secretion by CD4⁺ T cells in hepatocellular carcinoma. [Abstract]2025 Dec;48(11-12):1382-1398. PMID: 41284118 -
J Immunol
Sustained antigen-specific CD8+ T cell immunity post-mRNA booster requires notch pathway activation. [Abstract]2026 Jun 7;215(6):vkag074. PMID: 42258807 -
Genomics
Hypoxic environment promotes angiogenesis and bone bridge formation by activating Notch/RBPJ signaling pathway in HUVECs. [Abstract]2024 May;116(3):110838. PMID: 38537807 -
Tissue Cell
Overcoming osimertinib resistance in NSCLC: The role of Notch1 pathway inhibition by berberine. [Abstract]2026 Jun:100:103365. PMID: 41687187 -
Int J Lab Hematol
RBPJ/PAF1 Signaling Axis Promotes Cloning Expansion in Paroxysmal Nocturnal Hemoglobinuria Through NOTCH Signaling. [Abstract]2025 Jun 12. PMID: 40501337 -
bioRxiv
Graded Notch Signaling Functions as a Rheostat of Lineage Plasticity and Therapy Resistance in Prostate Cancer. [Abstract]2025 Nov 26:2025.11.23.690056. PMID: 41394651
Solvent & Solubility
DMSO : 100 mg/mL (321.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2122 mL | 16.0612 mL | 32.1223 mL | 80.3058 mL |
| 5 mM | 0.6424 mL | 3.2122 mL | 6.4245 mL | 16.0612 mL | |
| 10 mM | 0.3212 mL | 1.6061 mL | 3.2122 mL | 8.0306 mL | |
| 15 mM | 0.2141 mL | 1.0707 mL | 2.1415 mL | 5.3537 mL | |
| 20 mM | 0.1606 mL | 0.8031 mL | 1.6061 mL | 4.0153 mL | |
| 25 mM | 0.1285 mL | 0.6424 mL | 1.2849 mL | 3.2122 mL | |
| 30 mM | 0.1071 mL | 0.5354 mL | 1.0707 mL | 2.6769 mL | |
| 40 mM | 0.0803 mL | 0.4015 mL | 0.8031 mL | 2.0076 mL | |
| 50 mM | 0.0642 mL | 0.3212 mL | 0.6424 mL | 1.6061 mL | |
| 60 mM | 0.0535 mL | 0.2677 mL | 0.5354 mL | 1.3384 mL | |
| 80 mM | 0.0402 mL | 0.2008 mL | 0.4015 mL | 1.0038 mL | |
| 100 mM | 0.0321 mL | 0.1606 mL | 0.3212 mL | 0.8031 mL |
Powered by Bioz